Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.25 Consensus Target Price from Analysts
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The […]
